Concepedia

Egon Pfarr

EP

14

Publications

2.5K

Citations

14

H-Index

1997

Active since

Affiliations

Boehringer Ingelheim (Germany)(Current)

The University of Texas Southwestern Medical Center

Dallas Diabetes Research Center

Monash University

Boehringer Ingelheim (Norway)

Egon Pfarr is an author at Boehringer Ingelheim (Germany) specializing in medicine, cardiovascular disease, and pharmacology.

Top concepts

Publications per year

1997–2021

14

Publications

14

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA · 2018 · 1K citations · Full text

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA · 2019 · 578 citations · Full text

Darusentan: An effective endothelinA receptor antagonist for treatment of hypertension

Roumen Nakov, Egon Pfarr, Siegfried Eberle et al. · American Journal of Hypertension · 2002 · 172 citations · Full text

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

David Z.I. Cherney, Søren S. Lund, Bruce A. Perkins et al. · Diabetologia · 2016 · 171 citations · Full text

, , +9

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Darren K. McGuire, John H. Alexander, Odd Erik Johansen et al. · Circulation · 2019 · 157 citations · Full text

Rows per page

1–5 of 14